Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-19T14:16:02.063Z Has data issue: false hasContentIssue false

Chapter 3 - Neuroleptic malignant syndrome

Published online by Cambridge University Press:  05 July 2015

By
Atbin Djamashidian  and
Sean S. O’Sullivan
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 31 - 43
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Robottom, BJ, Weiner, WJ, Factor, SA. Movement disorders emergencies. Part 1: Hypokinetic disorders. Archives of Neurology. 2011;68(5):567–72. Epub 2011/05/11.Google ScholarPubMed
Preston, J. Central nervous system reactions to small doses of tranquilizers; report of one death. American Practitioner and Digest of Treatment. 1959;10(4):627–30. Epub 1959/04/01.Google ScholarPubMed
Delay, J, Pichot, P, Lemperiere, T, Ellisalde, B, Peigne, F. Un neuroleptique majeur non phenothiazine et non reserpinique l’haloperidol dans le traitment des psychoses. Ann Med Psychol. 1960;118:145–152.Google Scholar
Mann, SC, Caroff, S, Lazerus, A, Keck, PE. Neuroleptic malignant syndrome and related conditions. American Psychiatric Pub. 2008.Google Scholar
Caroff, SN. The neuroleptic malignant syndrome. The Journal of Clinical Psychiatry. 1980;41(3):79–83. Epub 1980/03/01.Google ScholarPubMed
Caroff, SN, Mann, SC, Sullivan, K, Campbell, B. Neuroleptic malignant syndrome in movement disorder emergencies: diagnosis and treatment. 2013:43–57.CrossRefGoogle Scholar
Lieberman, JA, Tasman, A. Antipsychotic drugs. In: Lieberman, JA, Tasman, A, editors. Handbook of Psychiatric Drugs. Chichester, England: John Wiley & Sons; 2006.CrossRefGoogle Scholar
Chaimowitz, GA, Gomes, U, Maze, SS. Neuroleptic malignant syndrome. CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne. 1988;138(1):51–3. Epub 1988/01/01.Google ScholarPubMed
Sing, A. Neuroleptic malignant syndrome. Br Med J (Clin Res Ed). 1983;287(6391):560–1. Epub 1983/08/20.Google Scholar
Friedman, JH, Davis, R, Wagner, RL. Neuroleptic malignant syndrome. The results of a 6-month prospective study of incidence in a state psychiatric hospital. Clinical Neuropharmacology. 1988; 11(4):373–7.Epub 1988/08/01.CrossRefGoogle Scholar
Keck, PE Jr., Sebastianelli, J, Pope, HG Jr., McElroy, SL. Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. The Journal of Clinical Psychiatry. 1989;50(9):352–5. Epub 1989/09/01.Google Scholar
Mehndiratta, P, Spolter, Y, Igboeli, B, Sajatovic, M, Buckley, P. Neuroleptic Malignant Syndrome. Neuromuscular Disorders in Clinical Practice. New York: Springer, 2014:1487–500.Google Scholar
Croarkin, PE, Emslie, GJ, Mayes, TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. The Journal of Clinical Psychiatry. 2008;69(7):1157–65. Epub 2008/06/25.CrossRefGoogle ScholarPubMed
Margetic, B, Aukst-Margetic, B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiology and Drug Safety. 2010;19(5):429–35. Epub 2010/03/23.CrossRefGoogle ScholarPubMed
Alexander, PJ, Thomas, RM, Das, A. Is risk of neuroleptic malignant syndrome increased in the postpartum period? The Journal of Clinical Psychiatry. 1998;59(5):254–5. Epub 1998/06/19.CrossRefGoogle ScholarPubMed
Rosebush, P, Stewart, T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. The American Journal of Psychiatry. 1989;146(6):717–25. Epub 1989/06/01.Google ScholarPubMed
Addonizio, G, Susman, VL, Roth, SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biological Psychiatry. 1987;22(8):1004–20. Epub 1987/08/01.CrossRefGoogle ScholarPubMed
Friedman, LS, Weinrauch, LA, D’Elia, JA. Metoclopramide-induced neuroleptic malignant syndrome. Archives of Internal Medicine. 1987;147(8):1495–7. Epub 1987/08/01.CrossRefGoogle ScholarPubMed
Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Psychopharmacology Bulletin. 1988;24(1):25–9. Epub 1988/01/01.Google ScholarPubMed
Stubner, S, Rustenbeck, E, Grohmann, R, Wagner, G, Engel, R, Neundorfer, G, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37 Suppl 1: S54–64.Epub 2004/03/31.Google ScholarPubMed
Ohkoshi, N, Satoh, D, Nishi, M, Shoji, S. Neuroleptic malignant-like syndrome due to donepezil and maprotiline. Neurology. 2003;60(6):1050–1. Epub 2003/03/26.CrossRefGoogle ScholarPubMed
Aisen, PS, Lawlor, BA. Neuroleptic malignant syndrome induced by low-dose haloperidol. The American Journal of Psychiatry. 1992;149(6):844. Epub 1992/06/01.Google ScholarPubMed
Tural, U, Onder, E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry and Clinical Neurosciences. 2010;64(1):79–87. Epub 2010/04/27.CrossRefGoogle ScholarPubMed
Adnet, P, Lestavel, P, Krivosic-Horber, R. Neuroleptic malignant syndrome. British Journal of Anaesthesia. 2000;85(1):129–35. Epub 2000/08/06.CrossRefGoogle ScholarPubMed
Levenson, JL. Neuroleptic malignant syndrome. The American Journal of Psychiatry. 1985;142(10):1137–45. Epub 1985/10/01.Google ScholarPubMed
Akpaffiong, MJ, Ruiz, P. Neuroleptic malignant syndrome: a complication of neuroleptics and cocaine abuse. The Psychiatric Quarterly. 1991;62(4):299–309. Epub 1991/01/01.CrossRefGoogle ScholarPubMed
White, DA, Robins, AH. Catatonia: harbinger of the neuroleptic malignant syndrome. The British Journal of Psychiatry: The Journal of Mental Science. 1991;158:419–21. Epub 1991/03/01.CrossRefGoogle ScholarPubMed
Hermesh, H, Manor, I, Shiloh, R, Aizenberg, D, Benjamini, Y, Munitz, H, et al. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. Journal of Clinical Psychopharmacology. 2002;22(3):252–6. Epub 2002/05/15.CrossRefGoogle ScholarPubMed
Reeves, RR, Mack, JE, Torres, RA. Neuroleptic malignant syndrome during a change from haloperidol to risperidone. The Annals of Pharmacotherapy. 2001;35(6):698–701. Epub 2001/06/21.CrossRefGoogle ScholarPubMed
Amore, M, Zazzeri, N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Progress in Neuropsychopharmacology and Biological Psychiatry. 1995;19(8):1323–34. Epub 1995/12/01.CrossRefGoogle ScholarPubMed
Otani, K, Horiuchi, M, Kondo, T, Kaneko, S, Fukushima, Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? The British Journal of Psychiatry: The Journal of Mental Science. 1991;158:850–3. Epub 1991/06/01.CrossRefGoogle ScholarPubMed
Kawanishi, C. Genetic predisposition to neuroleptic malignant syndrome: implications for antipsychotic therapy. American Journal of Pharmacogenomics: Genomics-Related Research in Drug Development and Clinical Practice. 2003;3(2):89–95. Epub 2003/05/17.CrossRefGoogle ScholarPubMed
Kawanishi, C, Hanihara, T, Shimoda, Y, Suzuki, K, Sugiyama, N, Onishi, H, et al. Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. The American Journal of Psychiatry. 1998;155(9):1275–7. Epub 1998/09/12.CrossRefGoogle ScholarPubMed
Suzuki, A, Kondo, T, Otani, K, Mihara, K, Yasui-Furukori, N, Sano, A, et al. Association of the TaqIA polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. The American Journal of Psychiatry. 2001;158(10):1714–6. Epub 2001/10/02.CrossRefGoogle Scholar
Kishida, I, Kawanishi, C, Furuno, T, Kato, D, Ishigami, T, Kosaka, K. Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Molecular Psychiatry. 2004;9(3):293–8. Epub 2004/04/20.CrossRefGoogle ScholarPubMed
Trollor, JN, Chen, X, Chitty, K, Sachdev, PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. The British Journal of Psychiatry: The Journal of Mental Science. 2012;201(1):52–6. Epub 2012/05/26.CrossRefGoogle ScholarPubMed
Guerra, R, Caroff, SN, Cohen, A, Carroll, B, De Roos, F, Francis, A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;Sep;72(9):1222–8.Google Scholar
Gurrera, RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. The American Journal of Psychiatry. 1999;156(2):169–80. Epub 1999/02/16.CrossRefGoogle ScholarPubMed
Velamoor, VR, Norman, RM, Caroff, SN, Mann, SC, Sullivan, KA, Antelo, RE. Progression of symptoms in neuroleptic malignant syndrome. The Journal of Nervous and Mental Disease. 1994;182(3):168–73. Epub 1994/03/01.CrossRefGoogle ScholarPubMed
Gurrera, RJ, Velamoor, V, Cernovsky, ZZ. A Validation study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. Journal of Clinical Psychopharmacology. 2013. Epub 2013/08/27.CrossRefGoogle Scholar
Kurlan, R, Hamill, R, Shoulson, I. Neuroleptic malignant syndrome. Clinical Neuropharmacology. 1984;7(2):109–20. Epub 1984/01/01.CrossRefGoogle ScholarPubMed
Sewell, DD, Jeste, DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases. The Journal of Neuropsychiatry and Clinical Neurosciences. 1992;4(3):265–9. Epub 1992/01/01.Google Scholar
Pelonero, AL, Levenson, JL, Pandurangi, AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49(9):1163–72. Epub 1998/09/15.CrossRefGoogle ScholarPubMed
Shalev, A, Hermesh, H, Munitz, H. Mortality from neuroleptic malignant syndrome. The Journal of Clinical Psychiatry. 1989;50(1):18–25. Epub 1989/01/01.Google ScholarPubMed
Nisijima, K, Ishiguro, T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. Journal of Psychiatric Research. 1995;29(3):233–44. Epub 1995/05/01.CrossRefGoogle ScholarPubMed
Burke, RE, Fahn, S, Mayeux, R, Weinberg, H, Louis, K, Willner, JH. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology. 1981;31(8):1022–5. Epub 1981/08/01.CrossRefGoogle Scholar
Cechetto, DF, Saper, CB. Neurochemical organization of the hypothalamic projection to the spinal cord in the rat. The Journal of Comparative Neurology. 1988;272(4):579–604. Epub 1988/06/22.CrossRefGoogle Scholar
Cox, B, Kerwin, R, Lee, TF. Dopamine receptors in the central thermoregulatory pathways of the rat. The Journal of Physiology. 1978;282:471–83. Epub 1978/09/01.CrossRefGoogle ScholarPubMed
Henderson, VW, Wooten, GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology. 1981;31(2):132–7. Epub 1981/02/01.Google ScholarPubMed
Kelkar, VV, Doctor, RB, Jindal, MN. Chlorpromazine-induced contracture of frog rectus abdominis muscle. Pharmacology. 1974;12(1):32–8. Epub 1974/01/01.CrossRefGoogle ScholarPubMed
Adnet, PJ, Krivosic-Horber, RM, Adamantidis, MM, Haudecoeur, G, Adnet-Bonte, CA, Saulnier, F, et al. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiologica Scandinavica. 1989;33(8):676–80. Epub 1989/11/01.CrossRefGoogle ScholarPubMed
Weller, M, Kornhuber, J. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Medical Hypotheses. 1992;38(4):329–33. Epub 1992/08/01.CrossRefGoogle ScholarPubMed
Anglin, RE, Rosebush, PI, Mazurek, MF. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne. 2010;182(18):E834–8. Epub 2010/08/11.CrossRefGoogle ScholarPubMed
Wijdicks, E. Neuroleptic malignant syndrome. In: Aminoff, MJ, Wilterdink, JL, eds. UpToDate: wwwUptodatecom. 2013.Google Scholar
Lee, JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biological Psychiatry. 1998;44(6):499–507. Epub 1998/10/20.CrossRefGoogle ScholarPubMed
Strawn, JR, Keck, PE Jr., Caroff, SN. Neuroleptic malignant syndrome. The American Journal of Psychiatry. 2007;164(6):870–6. Epub 2007/06/02.CrossRefGoogle ScholarPubMed
Wieselgren, IM, Lindstrom, LH. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Research. 1998;81(2):101–10. Epub 1998/12/19.CrossRefGoogle ScholarPubMed
Lyons, JL, Cohen, AB. Selective cerebellar and basal ganglia injury in neuroleptic malignant syndrome. Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging. 2013;23(2):240–1. Epub 2011/03/23.CrossRefGoogle ScholarPubMed
Sechi, GP, Tanda, F, Mutani, R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology. 1984;34(2):249–51. Epub 1984/02/01.CrossRefGoogle ScholarPubMed
Newman, EJ, Grosset, DG, Kennedy, PG. The parkinsonism-hyperpyrexia syndrome. Neurocritical Care. 2009;10(1):136–40. Epub 2008/08/21.CrossRefGoogle ScholarPubMed
Sato, Y, Asoh, T, Metoki, N, Satoh, K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2003;74(5):574–6. Epub 2003/04/18.CrossRefGoogle Scholar
Chalasani, P, Healy, D, Morriss, R. Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales. Psychological Medicine. 2005;35(11):1667–75. Epub 2005/10/13.CrossRefGoogle ScholarPubMed
Castillo, E, Rubin, RT, Holsboer-Trachsler, E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. The American Journal of Psychiatry. 1989;146(3):324–8. Epub 1989/03/01.Google ScholarPubMed
Rosebush, PI, Mazurek, MF. Catatonia and its treatment. Schizophrenia Bulletin. 2010;36(2):239–42. Epub 2009/12/09.CrossRefGoogle ScholarPubMed
Perry, PJ, Wilborn, CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists. 2012;24(2):155–62. Epub 2012/05/09.Google ScholarPubMed
Musselman, ME, Saely, S. Diagnosis and treatment of drug-induced hyperthermia. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists. 2013;70(1):34–42. Epub 2012/12/25.CrossRefGoogle ScholarPubMed
Munhoz, RP, Moscovich, M, Araujo, PD, Teive, HA. Movement disorders emergencies: a review. Arquivos de Neuro-Psiquiatria. 2012;70(6):453–61. Epub 2012/06/16.CrossRefGoogle ScholarPubMed
Huerta-Alardin, AL, Varon, J, Marik, PE. Bench-to-bedside review: Rhabdomyolysis – an overview for clinicians. Crit Care. 2005;9(2):158–69. Epub 2005/03/19.Google ScholarPubMed
Caroff, S, Mann, SC, Stephan, C, Lazarus, A, Sullivan, K, Macfadden, W. Neuroleptic malignant syndrome: Diagnostic issues. Psychiatric Annals. 1991;21(3):130–47.CrossRefGoogle Scholar
Lowy, A, Wilson, A, Sachdev, P, Lindeman, R. Disseminated intravascular coagulopathy and thrombocytopenia associated with clozapine-induced neuroleptic malignant syndrome. Australian and New Zealand Journal of Medicine. 1995;25(4):368. Epub 1995/08/01.CrossRefGoogle ScholarPubMed
Bienvenu, OJ, Neufeld, KJ, Needham, DM. Treatment of four psychiatric emergencies in the intensive care unit. Critical Care Medicine. 2012;40(9):2662–70. Epub 2012/06/27.Google ScholarPubMed
Diedler, J, Mellado, P, Veltkamp, R. Endovascular cooling in a patient with neuroleptic malignant syndrome. Journal of the Neurological Sciences. 2008; 264 (1–2): 163–5. Epub 2007/08/21.CrossRefGoogle Scholar
Gregorakos, L, Thomaides, T, Stratouli, S, Sakayanni, E. The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome. Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society. 2000;10(4):193–6. Epub 2000/10/12.CrossRefGoogle ScholarPubMed
Keck, PE Jr., Pope, HG Jr., Cohen, BM, McElroy, SL, Nierenberg, AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Archives of General Psychiatry. 1989;46(10):914–8. Epub 1989/10/01.CrossRefGoogle ScholarPubMed
Rosenberg, MR, Green, M. Neuroleptic malignant syndrome. Review of response to therapy. Archives of Internal Medicine. 1989;149(9):1927–31. Epub 1989/09/01.CrossRefGoogle ScholarPubMed
Serrano-Duenas, M. Neuroleptic malignant syndrome-like, or–dopaminergic malignant syndrome–due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism and Related Disorders. 2003;9(3):175–8. Epub 2003/02/08.CrossRefGoogle ScholarPubMed
Reulbach, U, Dutsch, C, Biermann, T, Sperling, W, Thuerauf, N, Kornhuber, J, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11(1): R4. Epub 2007/01/16.CrossRefGoogle ScholarPubMed
Trollor, JN, Sachdev, PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. The Australian and New Zealand Journal of Psychiatry. 1999;33(5):650–9. Epub 1999/11/02.CrossRefGoogle ScholarPubMed
Lee, S, Merriam, A, Kim, TS, Liebling, M, Dickson, DW, Moore, GR. Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury. Journal of Neurology, Neurosurgery, and Psychiatry. 1989;52(3):387–91. Epub 1989/03/01.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×